nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PPARG—psoriasis	0.362	1	CbGaD
Mesalazine—MPO—Calcipotriol—psoriasis	0.279	0.803	CbGbCtD
Mesalazine—PTGS2—Triamcinolone—psoriasis	0.029	0.0836	CbGbCtD
Mesalazine—PTGS2—Betamethasone—psoriasis	0.0249	0.0718	CbGbCtD
Mesalazine—PTGS2—Dexamethasone—psoriasis	0.0145	0.0417	CbGbCtD
Mesalazine—PPARG—dermis—psoriasis	0.00598	0.235	CbGeAlD
Mesalazine—PTGS2—skeletal joint—psoriasis	0.00264	0.104	CbGeAlD
Mesalazine—MPO—endothelium—psoriasis	0.00206	0.0809	CbGeAlD
Mesalazine—PTGS2—synovial membrane of synovial joint—psoriasis	0.002	0.0788	CbGeAlD
Mesalazine—CHUK—skin of body—psoriasis	0.00184	0.0724	CbGeAlD
Mesalazine—PPARG—endothelium—psoriasis	0.00183	0.0718	CbGeAlD
Mesalazine—Olsalazine—IFNG—psoriasis	0.00159	0.68	CrCbGaD
Mesalazine—PTGS2—skin epidermis—psoriasis	0.00129	0.0505	CbGeAlD
Mesalazine—IKBKB—skin of body—psoriasis	0.00125	0.0492	CbGeAlD
Mesalazine—PTGS1—endothelium—psoriasis	0.000976	0.0384	CbGeAlD
Mesalazine—IKBKB—tendon—psoriasis	0.000953	0.0375	CbGeAlD
Mesalazine—PTGS2—endothelium—psoriasis	0.000933	0.0367	CbGeAlD
Mesalazine—MPO—skin of body—psoriasis	0.000878	0.0345	CbGeAlD
Mesalazine—PPARG—skin of body—psoriasis	0.000779	0.0306	CbGeAlD
Mesalazine—Olsalazine—PPARG—psoriasis	0.000747	0.32	CrCbGaD
Mesalazine—PPARG—tendon—psoriasis	0.000593	0.0233	CbGeAlD
Mesalazine—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.00045	0.157	CbGdCrCtD
Mesalazine—PTGS1—skin of body—psoriasis	0.000417	0.0164	CbGeAlD
Mesalazine—PTGS2—skin of body—psoriasis	0.000398	0.0157	CbGeAlD
Mesalazine—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000361	0.126	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.00035	0.122	CbGdCrCtD
Mesalazine—PTGS1—tendon—psoriasis	0.000317	0.0125	CbGeAlD
Mesalazine—PTGS2—tendon—psoriasis	0.000303	0.0119	CbGeAlD
Mesalazine—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000272	0.0948	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000218	0.076	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000218	0.076	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000211	0.0738	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000164	0.0574	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000164	0.0574	CbGdCrCtD
Mesalazine—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000161	0.0561	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	9.92e-05	0.0346	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	9.92e-05	0.0346	CbGdCrCtD
Mesalazine—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	9.69e-05	0.0338	CbGdCrCtD
Mesalazine—CHUK—Signaling Pathways—TAGAP—psoriasis	3.43e-05	0.000338	CbGpPWpGaD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	3.4e-05	0.000334	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—JUN—psoriasis	3.39e-05	0.000334	CbGpPWpGaD
Mesalazine—CHUK—MyD88-independent cascade—IL6—psoriasis	3.39e-05	0.000334	CbGpPWpGaD
Mesalazine—IKBKB—MyD88 dependent cascade initiated on endosome—IL6—psoriasis	3.38e-05	0.000333	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—ICAM1—psoriasis	3.37e-05	0.000332	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.36e-05	0.000331	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—IFNG—psoriasis	3.34e-05	0.000329	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—JUN—psoriasis	3.33e-05	0.000328	CbGpPWpGaD
Mesalazine—IKBKB—TCR Signaling Pathway—IL6—psoriasis	3.32e-05	0.000327	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	3.32e-05	0.000327	CbGpPWpGaD
Mesalazine—CHUK—Toll-like Receptor Signaling Pathway—IL6—psoriasis	3.31e-05	0.000326	CbGpPWpGaD
Mesalazine—CHUK—Downstream signal transduction—STAT3—psoriasis	3.29e-05	0.000324	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—NFKBIA—psoriasis	3.29e-05	0.000323	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HLA-E—psoriasis	3.26e-05	0.000321	CbGpPWpGaD
Mesalazine—IKBKB—BDNF signaling pathway—STAT3—psoriasis	3.26e-05	0.000321	CbGpPWpGaD
Mesalazine—IKBKB—TNF alpha Signaling Pathway—IL6—psoriasis	3.26e-05	0.000321	CbGpPWpGaD
Mesalazine—IKBKB—Toll Like Receptor 9 (TLR9) Cascade—IL6—psoriasis	3.26e-05	0.000321	CbGpPWpGaD
Mesalazine—IKBKB—Downstream signaling events of B Cell Receptor (BCR)—NFKB1—psoriasis	3.23e-05	0.000317	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—NFKB1—psoriasis	3.21e-05	0.000316	CbGpPWpGaD
Mesalazine—IKBKB—MyD88:Mal cascade initiated on plasma membrane—IL6—psoriasis	3.21e-05	0.000316	CbGpPWpGaD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	3.2e-05	0.000315	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	3.2e-05	0.000315	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.19e-05	0.000314	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP2S1—psoriasis	3.19e-05	0.000314	CbGpPWpGaD
Mesalazine—CHUK—Signaling by Interleukins—IL6—psoriasis	3.16e-05	0.000311	CbGpPWpGaD
Mesalazine—CHUK—B Cell Activation—NFKB1—psoriasis	3.14e-05	0.000309	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HLA-E—psoriasis	3.13e-05	0.000308	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TAGAP—psoriasis	3.11e-05	0.000306	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	3.11e-05	0.000306	CbGpPWpGaD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	3.08e-05	0.000303	CbGpPWpGaD
Mesalazine—IKBKB—MyD88-independent cascade—IL6—psoriasis	3.08e-05	0.000303	CbGpPWpGaD
Mesalazine—CHUK—Activated TLR4 signalling—IL6—psoriasis	3.05e-05	0.0003	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—STAT3—psoriasis	3.05e-05	0.0003	CbGpPWpGaD
Mesalazine—Discomfort—Dexamethasone—psoriasis	3.04e-05	0.000192	CcSEcCtD
Mesalazine—Dyspepsia—Hydrocortisone—psoriasis	3.04e-05	0.000191	CcSEcCtD
Mesalazine—Haemoglobin—Methotrexate—psoriasis	3.04e-05	0.000191	CcSEcCtD
Mesalazine—Rash—Mycophenolic acid—psoriasis	3.03e-05	0.000191	CcSEcCtD
Mesalazine—Dermatitis—Mycophenolic acid—psoriasis	3.02e-05	0.000191	CcSEcCtD
Mesalazine—Pain—Prednisolone—psoriasis	3.02e-05	0.00019	CcSEcCtD
Mesalazine—Hepatitis—Methotrexate—psoriasis	3.02e-05	0.00019	CcSEcCtD
Mesalazine—Haemorrhage—Methotrexate—psoriasis	3.02e-05	0.00019	CcSEcCtD
Mesalazine—CHUK—Cytokine Signaling in Immune system—TYK2—psoriasis	3.02e-05	0.000297	CbGpPWpGaD
Mesalazine—Urticaria—Mycophenolate mofetil—psoriasis	3.01e-05	0.00019	CcSEcCtD
Mesalazine—Headache—Mycophenolic acid—psoriasis	3.01e-05	0.00019	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—SOCS1—psoriasis	3.01e-05	0.000296	CbGpPWpGaD
Mesalazine—IKBKB—Toll-like Receptor Signaling Pathway—IL6—psoriasis	3e-05	0.000296	CbGpPWpGaD
Mesalazine—Decreased appetite—Hydrocortisone—psoriasis	3e-05	0.000189	CcSEcCtD
Mesalazine—Pharyngitis—Methotrexate—psoriasis	3e-05	0.000189	CcSEcCtD
Mesalazine—Body temperature increased—Mycophenolate mofetil—psoriasis	2.99e-05	0.000189	CcSEcCtD
Mesalazine—Abdominal pain—Mycophenolate mofetil—psoriasis	2.99e-05	0.000189	CcSEcCtD
Mesalazine—CHUK—Signaling by PDGF—STAT3—psoriasis	2.98e-05	0.000294	CbGpPWpGaD
Mesalazine—Urinary tract disorder—Methotrexate—psoriasis	2.98e-05	0.000188	CcSEcCtD
Mesalazine—PTGS2—Metabolism—NDUFA5—psoriasis	2.98e-05	0.000293	CbGpPWpGaD
Mesalazine—Gastrointestinal disorder—Hydrocortisone—psoriasis	2.98e-05	0.000188	CcSEcCtD
Mesalazine—Fatigue—Hydrocortisone—psoriasis	2.97e-05	0.000188	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—TYK2—psoriasis	2.97e-05	0.000292	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.97e-05	0.000292	CbGpPWpGaD
Mesalazine—Vision blurred—Prednisone—psoriasis	2.96e-05	0.000187	CcSEcCtD
Mesalazine—Urethral disorder—Methotrexate—psoriasis	2.96e-05	0.000187	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Triamcinolone—psoriasis	2.96e-05	0.000187	CcSEcCtD
Mesalazine—Pain—Hydrocortisone—psoriasis	2.95e-05	0.000186	CcSEcCtD
Mesalazine—Oedema—Betamethasone—psoriasis	2.95e-05	0.000186	CcSEcCtD
Mesalazine—Oedema—Dexamethasone—psoriasis	2.95e-05	0.000186	CcSEcCtD
Mesalazine—Anaphylactic shock—Betamethasone—psoriasis	2.95e-05	0.000186	CcSEcCtD
Mesalazine—Anaphylactic shock—Dexamethasone—psoriasis	2.95e-05	0.000186	CcSEcCtD
Mesalazine—Insomnia—Triamcinolone—psoriasis	2.94e-05	0.000185	CcSEcCtD
Mesalazine—CHUK—Immune System—ITGAL—psoriasis	2.93e-05	0.000289	CbGpPWpGaD
Mesalazine—Infection—Betamethasone—psoriasis	2.93e-05	0.000185	CcSEcCtD
Mesalazine—Infection—Dexamethasone—psoriasis	2.93e-05	0.000185	CcSEcCtD
Mesalazine—Ill-defined disorder—Prednisone—psoriasis	2.92e-05	0.000184	CcSEcCtD
Mesalazine—Paraesthesia—Triamcinolone—psoriasis	2.92e-05	0.000184	CcSEcCtD
Mesalazine—Feeling abnormal—Prednisolone—psoriasis	2.91e-05	0.000184	CcSEcCtD
Mesalazine—Anaemia—Prednisone—psoriasis	2.91e-05	0.000183	CcSEcCtD
Mesalazine—PPARG—Adipogenesis—IL6—psoriasis	2.91e-05	0.000286	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—TNF—psoriasis	2.91e-05	0.000286	CbGpPWpGaD
Mesalazine—Shock—Dexamethasone—psoriasis	2.9e-05	0.000183	CcSEcCtD
Mesalazine—Shock—Betamethasone—psoriasis	2.9e-05	0.000183	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.9e-05	0.000285	CbGpPWpGaD
Mesalazine—Dyspnoea—Triamcinolone—psoriasis	2.9e-05	0.000183	CcSEcCtD
Mesalazine—Nervous system disorder—Betamethasone—psoriasis	2.89e-05	0.000182	CcSEcCtD
Mesalazine—Nervous system disorder—Dexamethasone—psoriasis	2.89e-05	0.000182	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—SOCS1—psoriasis	2.89e-05	0.000284	CbGpPWpGaD
Mesalazine—Thrombocytopenia—Betamethasone—psoriasis	2.89e-05	0.000182	CcSEcCtD
Mesalazine—Thrombocytopenia—Dexamethasone—psoriasis	2.89e-05	0.000182	CcSEcCtD
Mesalazine—Tachycardia—Dexamethasone—psoriasis	2.88e-05	0.000181	CcSEcCtD
Mesalazine—Tachycardia—Betamethasone—psoriasis	2.88e-05	0.000181	CcSEcCtD
Mesalazine—Angioedema—Prednisone—psoriasis	2.87e-05	0.000181	CcSEcCtD
Mesalazine—CHUK—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	2.87e-05	0.000282	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by Interleukins—IL6—psoriasis	2.87e-05	0.000282	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—CARM1—psoriasis	2.86e-05	0.000282	CbGpPWpGaD
Mesalazine—Hypersensitivity—Cyclosporine—psoriasis	2.86e-05	0.00018	CcSEcCtD
Mesalazine—Dyspepsia—Triamcinolone—psoriasis	2.86e-05	0.00018	CcSEcCtD
Mesalazine—Erythema multiforme—Methotrexate—psoriasis	2.86e-05	0.00018	CcSEcCtD
Mesalazine—Nausea—Mycophenolic acid—psoriasis	2.85e-05	0.00018	CcSEcCtD
Mesalazine—Hyperhidrosis—Betamethasone—psoriasis	2.85e-05	0.00018	CcSEcCtD
Mesalazine—Hyperhidrosis—Dexamethasone—psoriasis	2.85e-05	0.00018	CcSEcCtD
Mesalazine—IKBKB—B Cell Activation—NFKB1—psoriasis	2.85e-05	0.00028	CbGpPWpGaD
Mesalazine—Feeling abnormal—Hydrocortisone—psoriasis	2.84e-05	0.000179	CcSEcCtD
Mesalazine—Malaise—Prednisone—psoriasis	2.84e-05	0.000179	CcSEcCtD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IFNG—psoriasis	2.83e-05	0.000278	CbGpPWpGaD
Mesalazine—Vertigo—Prednisone—psoriasis	2.83e-05	0.000178	CcSEcCtD
Mesalazine—Eye disorder—Methotrexate—psoriasis	2.82e-05	0.000178	CcSEcCtD
Mesalazine—Gastrointestinal pain—Hydrocortisone—psoriasis	2.82e-05	0.000178	CcSEcCtD
Mesalazine—Syncope—Prednisone—psoriasis	2.82e-05	0.000178	CcSEcCtD
Mesalazine—Tinnitus—Methotrexate—psoriasis	2.82e-05	0.000178	CcSEcCtD
Mesalazine—Anorexia—Betamethasone—psoriasis	2.81e-05	0.000177	CcSEcCtD
Mesalazine—Anorexia—Dexamethasone—psoriasis	2.81e-05	0.000177	CcSEcCtD
Mesalazine—Urticaria—Prednisolone—psoriasis	2.81e-05	0.000177	CcSEcCtD
Mesalazine—Cardiac disorder—Methotrexate—psoriasis	2.8e-05	0.000177	CcSEcCtD
Mesalazine—Fatigue—Triamcinolone—psoriasis	2.8e-05	0.000177	CcSEcCtD
Mesalazine—Hypersensitivity—Mycophenolate mofetil—psoriasis	2.79e-05	0.000176	CcSEcCtD
Mesalazine—Asthenia—Cyclosporine—psoriasis	2.79e-05	0.000176	CcSEcCtD
Mesalazine—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	2.78e-05	0.000274	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.78e-05	0.000274	CbGpPWpGaD
Mesalazine—Pain—Triamcinolone—psoriasis	2.78e-05	0.000175	CcSEcCtD
Mesalazine—IKBKB—Activated TLR4 signalling—IL6—psoriasis	2.77e-05	0.000272	CbGpPWpGaD
Mesalazine—Loss of consciousness—Prednisone—psoriasis	2.76e-05	0.000174	CcSEcCtD
Mesalazine—Hypotension—Betamethasone—psoriasis	2.75e-05	0.000174	CcSEcCtD
Mesalazine—Hypotension—Dexamethasone—psoriasis	2.75e-05	0.000174	CcSEcCtD
Mesalazine—Pruritus—Cyclosporine—psoriasis	2.75e-05	0.000173	CcSEcCtD
Mesalazine—CHUK—Immune System—REL—psoriasis	2.74e-05	0.00027	CbGpPWpGaD
Mesalazine—Urticaria—Hydrocortisone—psoriasis	2.74e-05	0.000173	CcSEcCtD
Mesalazine—Angiopathy—Methotrexate—psoriasis	2.74e-05	0.000173	CcSEcCtD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—TYK2—psoriasis	2.74e-05	0.000269	CbGpPWpGaD
Mesalazine—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	2.74e-05	0.000269	CbGpPWpGaD
Mesalazine—Immune system disorder—Methotrexate—psoriasis	2.73e-05	0.000172	CcSEcCtD
Mesalazine—Abdominal pain—Hydrocortisone—psoriasis	2.73e-05	0.000172	CcSEcCtD
Mesalazine—Body temperature increased—Hydrocortisone—psoriasis	2.73e-05	0.000172	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—SOCS1—psoriasis	2.73e-05	0.000268	CbGpPWpGaD
Mesalazine—Mediastinal disorder—Methotrexate—psoriasis	2.72e-05	0.000172	CcSEcCtD
Mesalazine—Asthenia—Mycophenolate mofetil—psoriasis	2.72e-05	0.000171	CcSEcCtD
Mesalazine—Hypertension—Prednisone—psoriasis	2.72e-05	0.000171	CcSEcCtD
Mesalazine—Chills—Methotrexate—psoriasis	2.71e-05	0.000171	CcSEcCtD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	2.7e-05	0.000266	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—TYK2—psoriasis	2.69e-05	0.000265	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Betamethasone—psoriasis	2.69e-05	0.000169	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Dexamethasone—psoriasis	2.69e-05	0.000169	CcSEcCtD
Mesalazine—Pruritus—Mycophenolate mofetil—psoriasis	2.68e-05	0.000169	CcSEcCtD
Mesalazine—Arthralgia—Prednisone—psoriasis	2.68e-05	0.000169	CcSEcCtD
Mesalazine—Myalgia—Prednisone—psoriasis	2.68e-05	0.000169	CcSEcCtD
Mesalazine—Feeling abnormal—Triamcinolone—psoriasis	2.68e-05	0.000169	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—LEP—psoriasis	2.68e-05	0.000263	CbGpPWpGaD
Mesalazine—Anxiety—Prednisone—psoriasis	2.67e-05	0.000168	CcSEcCtD
Mesalazine—Alopecia—Methotrexate—psoriasis	2.67e-05	0.000168	CcSEcCtD
Mesalazine—Insomnia—Dexamethasone—psoriasis	2.67e-05	0.000168	CcSEcCtD
Mesalazine—Insomnia—Betamethasone—psoriasis	2.67e-05	0.000168	CcSEcCtD
Mesalazine—CHUK—Immune System—IFIH1—psoriasis	2.66e-05	0.000262	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ITGAL—psoriasis	2.66e-05	0.000262	CbGpPWpGaD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	2.66e-05	0.000168	CcSEcCtD
Mesalazine—Diarrhoea—Cyclosporine—psoriasis	2.66e-05	0.000167	CcSEcCtD
Mesalazine—Paraesthesia—Dexamethasone—psoriasis	2.65e-05	0.000167	CcSEcCtD
Mesalazine—Paraesthesia—Betamethasone—psoriasis	2.65e-05	0.000167	CcSEcCtD
Mesalazine—Discomfort—Prednisone—psoriasis	2.65e-05	0.000167	CcSEcCtD
Mesalazine—Mental disorder—Methotrexate—psoriasis	2.65e-05	0.000167	CcSEcCtD
Mesalazine—CHUK—Integrated Breast Cancer Pathway—TP53—psoriasis	2.64e-05	0.00026	CbGpPWpGaD
Mesalazine—Erythema—Methotrexate—psoriasis	2.63e-05	0.000166	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—SOCS1—psoriasis	2.62e-05	0.000258	CbGpPWpGaD
Mesalazine—Hypersensitivity—Prednisolone—psoriasis	2.6e-05	0.000164	CcSEcCtD
Mesalazine—IKBKB—Toll Like Receptor 4 (TLR4) Cascade—IL6—psoriasis	2.6e-05	0.000256	CbGpPWpGaD
Mesalazine—Dyspepsia—Dexamethasone—psoriasis	2.59e-05	0.000164	CcSEcCtD
Mesalazine—Dyspepsia—Betamethasone—psoriasis	2.59e-05	0.000164	CcSEcCtD
Mesalazine—Diarrhoea—Mycophenolate mofetil—psoriasis	2.59e-05	0.000163	CcSEcCtD
Mesalazine—CHUK—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	2.59e-05	0.000254	CbGpPWpGaD
Mesalazine—Urticaria—Triamcinolone—psoriasis	2.58e-05	0.000163	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—psoriasis	2.57e-05	0.000162	CcSEcCtD
Mesalazine—Body temperature increased—Triamcinolone—psoriasis	2.57e-05	0.000162	CcSEcCtD
Mesalazine—Dizziness—Cyclosporine—psoriasis	2.57e-05	0.000162	CcSEcCtD
Mesalazine—Oedema—Prednisone—psoriasis	2.57e-05	0.000162	CcSEcCtD
Mesalazine—Anaphylactic shock—Prednisone—psoriasis	2.57e-05	0.000162	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—HLA-B—psoriasis	2.56e-05	0.000252	CbGpPWpGaD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IFNG—psoriasis	2.56e-05	0.000252	CbGpPWpGaD
Mesalazine—Decreased appetite—Betamethasone—psoriasis	2.56e-05	0.000162	CcSEcCtD
Mesalazine—Decreased appetite—Dexamethasone—psoriasis	2.56e-05	0.000162	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—CD8A—psoriasis	2.56e-05	0.000252	CbGpPWpGaD
Mesalazine—CHUK—Signaling by SCF-KIT—IL6—psoriasis	2.56e-05	0.000252	CbGpPWpGaD
Mesalazine—CHUK—Toll-Like Receptors Cascades—IL6—psoriasis	2.56e-05	0.000252	CbGpPWpGaD
Mesalazine—Infection—Prednisone—psoriasis	2.55e-05	0.000161	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Dexamethasone—psoriasis	2.55e-05	0.00016	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Betamethasone—psoriasis	2.55e-05	0.00016	CcSEcCtD
Mesalazine—Back pain—Methotrexate—psoriasis	2.54e-05	0.00016	CcSEcCtD
Mesalazine—Hypersensitivity—Hydrocortisone—psoriasis	2.54e-05	0.00016	CcSEcCtD
Mesalazine—Fatigue—Dexamethasone—psoriasis	2.54e-05	0.00016	CcSEcCtD
Mesalazine—Fatigue—Betamethasone—psoriasis	2.54e-05	0.00016	CcSEcCtD
Mesalazine—PTGS2—Metabolism—CYP2S1—psoriasis	2.54e-05	0.00025	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-C—psoriasis	2.53e-05	0.000249	CbGpPWpGaD
Mesalazine—Shock—Prednisone—psoriasis	2.53e-05	0.000159	CcSEcCtD
Mesalazine—Pain—Dexamethasone—psoriasis	2.52e-05	0.000159	CcSEcCtD
Mesalazine—Pain—Betamethasone—psoriasis	2.52e-05	0.000159	CcSEcCtD
Mesalazine—Nervous system disorder—Prednisone—psoriasis	2.52e-05	0.000159	CcSEcCtD
Mesalazine—Tachycardia—Prednisone—psoriasis	2.51e-05	0.000158	CcSEcCtD
Mesalazine—Dizziness—Mycophenolate mofetil—psoriasis	2.5e-05	0.000158	CcSEcCtD
Mesalazine—IKBKB—MAPK Signaling Pathway—TNF—psoriasis	2.5e-05	0.000246	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TNFAIP3—psoriasis	2.49e-05	0.000246	CbGpPWpGaD
Mesalazine—Skin disorder—Prednisone—psoriasis	2.49e-05	0.000157	CcSEcCtD
Mesalazine—IKBKB—Immune System—REL—psoriasis	2.49e-05	0.000245	CbGpPWpGaD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.48e-05	0.000245	CbGpPWpGaD
Mesalazine—Hyperhidrosis—Prednisone—psoriasis	2.48e-05	0.000156	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—psoriasis	2.48e-05	0.000156	CcSEcCtD
Mesalazine—Asthenia—Hydrocortisone—psoriasis	2.48e-05	0.000156	CcSEcCtD
Mesalazine—Vomiting—Cyclosporine—psoriasis	2.47e-05	0.000156	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—HLA-B—psoriasis	2.46e-05	0.000242	CbGpPWpGaD
Mesalazine—Rash—Cyclosporine—psoriasis	2.45e-05	0.000154	CcSEcCtD
Mesalazine—Anorexia—Prednisone—psoriasis	2.45e-05	0.000154	CcSEcCtD
Mesalazine—CHUK—Downstream signaling of activated FGFR—IL6—psoriasis	2.45e-05	0.000241	CbGpPWpGaD
Mesalazine—Dermatitis—Cyclosporine—psoriasis	2.45e-05	0.000154	CcSEcCtD
Mesalazine—Pruritus—Hydrocortisone—psoriasis	2.44e-05	0.000154	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—psoriasis	2.44e-05	0.000154	CcSEcCtD
Mesalazine—Headache—Cyclosporine—psoriasis	2.43e-05	0.000153	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—psoriasis	2.43e-05	0.000153	CcSEcCtD
Mesalazine—Feeling abnormal—Dexamethasone—psoriasis	2.43e-05	0.000153	CcSEcCtD
Mesalazine—Feeling abnormal—Betamethasone—psoriasis	2.43e-05	0.000153	CcSEcCtD
Mesalazine—IKBKB—Immune System—IFIH1—psoriasis	2.42e-05	0.000238	CbGpPWpGaD
Mesalazine—Gastrointestinal pain—Dexamethasone—psoriasis	2.41e-05	0.000152	CcSEcCtD
Mesalazine—Gastrointestinal pain—Betamethasone—psoriasis	2.41e-05	0.000152	CcSEcCtD
Mesalazine—Vomiting—Mycophenolate mofetil—psoriasis	2.41e-05	0.000152	CcSEcCtD
Mesalazine—CHUK—Signaling by ERBB4—IL6—psoriasis	2.41e-05	0.000237	CbGpPWpGaD
Mesalazine—Hypersensitivity—Triamcinolone—psoriasis	2.39e-05	0.000151	CcSEcCtD
Mesalazine—PPARG—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.39e-05	0.000235	CbGpPWpGaD
Mesalazine—Rash—Mycophenolate mofetil—psoriasis	2.39e-05	0.000151	CcSEcCtD
Mesalazine—Dermatitis—Mycophenolate mofetil—psoriasis	2.39e-05	0.00015	CcSEcCtD
Mesalazine—Headache—Mycophenolate mofetil—psoriasis	2.37e-05	0.00015	CcSEcCtD
Mesalazine—Malaise—Methotrexate—psoriasis	2.37e-05	0.000149	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—psoriasis	2.36e-05	0.000149	CcSEcCtD
Mesalazine—Diarrhoea—Hydrocortisone—psoriasis	2.36e-05	0.000149	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—psoriasis	2.35e-05	0.000148	CcSEcCtD
Mesalazine—CHUK—Cytokine Signaling in Immune system—NFKB1—psoriasis	2.35e-05	0.000231	CbGpPWpGaD
Mesalazine—IKBKB—Regulation of toll-like receptor signaling pathway—IL6—psoriasis	2.34e-05	0.000231	CbGpPWpGaD
Mesalazine—Urticaria—Betamethasone—psoriasis	2.34e-05	0.000148	CcSEcCtD
Mesalazine—Urticaria—Dexamethasone—psoriasis	2.34e-05	0.000148	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Prednisone—psoriasis	2.34e-05	0.000147	CcSEcCtD
Mesalazine—Dizziness—Prednisolone—psoriasis	2.34e-05	0.000147	CcSEcCtD
Mesalazine—Asthenia—Triamcinolone—psoriasis	2.33e-05	0.000147	CcSEcCtD
Mesalazine—Abdominal pain—Dexamethasone—psoriasis	2.33e-05	0.000147	CcSEcCtD
Mesalazine—Body temperature increased—Betamethasone—psoriasis	2.33e-05	0.000147	CcSEcCtD
Mesalazine—Body temperature increased—Dexamethasone—psoriasis	2.33e-05	0.000147	CcSEcCtD
Mesalazine—Abdominal pain—Betamethasone—psoriasis	2.33e-05	0.000147	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—HLA-B—psoriasis	2.33e-05	0.000229	CbGpPWpGaD
Mesalazine—Insomnia—Prednisone—psoriasis	2.32e-05	0.000146	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—CD8A—psoriasis	2.32e-05	0.000228	CbGpPWpGaD
Mesalazine—IKBKB—Toll-Like Receptors Cascades—IL6—psoriasis	2.32e-05	0.000228	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—NFKB1—psoriasis	2.31e-05	0.000228	CbGpPWpGaD
Mesalazine—Nausea—Cyclosporine—psoriasis	2.31e-05	0.000145	CcSEcCtD
Mesalazine—Paraesthesia—Prednisone—psoriasis	2.31e-05	0.000145	CcSEcCtD
Mesalazine—CHUK—Downstream signal transduction—IL6—psoriasis	2.3e-05	0.000226	CbGpPWpGaD
Mesalazine—Pruritus—Triamcinolone—psoriasis	2.3e-05	0.000145	CcSEcCtD
Mesalazine—Cough—Methotrexate—psoriasis	2.29e-05	0.000145	CcSEcCtD
Mesalazine—IKBKB—Immune System—HLA-C—psoriasis	2.29e-05	0.000225	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR—IL6—psoriasis	2.29e-05	0.000225	CbGpPWpGaD
Mesalazine—Dizziness—Hydrocortisone—psoriasis	2.28e-05	0.000144	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—HLA-A—psoriasis	2.28e-05	0.000225	CbGpPWpGaD
Mesalazine—CHUK—Signaling by ERBB2—IL6—psoriasis	2.28e-05	0.000224	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CRP—psoriasis	2.27e-05	0.000223	CbGpPWpGaD
Mesalazine—CHUK—DAP12 signaling—IL6—psoriasis	2.27e-05	0.000223	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TNFAIP3—psoriasis	2.26e-05	0.000223	CbGpPWpGaD
Mesalazine—Dyspepsia—Prednisone—psoriasis	2.26e-05	0.000142	CcSEcCtD
Mesalazine—Nausea—Mycophenolate mofetil—psoriasis	2.25e-05	0.000142	CcSEcCtD
Mesalazine—PPARG—Circadian rythm related genes—TP53—psoriasis	2.24e-05	0.00022	CbGpPWpGaD
Mesalazine—Myalgia—Methotrexate—psoriasis	2.24e-05	0.000141	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—psoriasis	2.24e-05	0.000141	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—psoriasis	2.24e-05	0.000141	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—HLA-B—psoriasis	2.23e-05	0.00022	CbGpPWpGaD
Mesalazine—Decreased appetite—Prednisone—psoriasis	2.23e-05	0.000141	CcSEcCtD
Mesalazine—Rash—Prednisolone—psoriasis	2.23e-05	0.00014	CcSEcCtD
Mesalazine—PPARG—Metabolism—CARM1—psoriasis	2.23e-05	0.000219	CbGpPWpGaD
Mesalazine—Dermatitis—Prednisolone—psoriasis	2.23e-05	0.00014	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	2.22e-05	0.00014	CcSEcCtD
Mesalazine—Fatigue—Prednisone—psoriasis	2.21e-05	0.00014	CcSEcCtD
Mesalazine—Headache—Prednisolone—psoriasis	2.21e-05	0.00014	CcSEcCtD
Mesalazine—ALOX5—Metabolism—CAT—psoriasis	2.21e-05	0.000218	CbGpPWpGaD
Mesalazine—Discomfort—Methotrexate—psoriasis	2.21e-05	0.000139	CcSEcCtD
Mesalazine—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	2.21e-05	0.000217	CbGpPWpGaD
Mesalazine—IKBKB—MAPK Signaling Pathway—TP53—psoriasis	2.2e-05	0.000217	CbGpPWpGaD
Mesalazine—Constipation—Prednisone—psoriasis	2.2e-05	0.000138	CcSEcCtD
Mesalazine—Vomiting—Hydrocortisone—psoriasis	2.19e-05	0.000138	CcSEcCtD
Mesalazine—CHUK—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.19e-05	0.000216	CbGpPWpGaD
Mesalazine—Rash—Hydrocortisone—psoriasis	2.18e-05	0.000137	CcSEcCtD
Mesalazine—Dermatitis—Hydrocortisone—psoriasis	2.17e-05	0.000137	CcSEcCtD
Mesalazine—PTGS2—Spinal Cord Injury—TNF—psoriasis	2.16e-05	0.000213	CbGpPWpGaD
Mesalazine—Confusional state—Methotrexate—psoriasis	2.16e-05	0.000136	CcSEcCtD
Mesalazine—Headache—Hydrocortisone—psoriasis	2.16e-05	0.000136	CcSEcCtD
Mesalazine—Dizziness—Triamcinolone—psoriasis	2.15e-05	0.000135	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—psoriasis	2.15e-05	0.000135	CcSEcCtD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—NFKB1—psoriasis	2.13e-05	0.00021	CbGpPWpGaD
Mesalazine—Infection—Methotrexate—psoriasis	2.13e-05	0.000134	CcSEcCtD
Mesalazine—CHUK—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	2.13e-05	0.00021	CbGpPWpGaD
Mesalazine—CHUK—Signaling by FGFR in disease—IL6—psoriasis	2.13e-05	0.00021	CbGpPWpGaD
Mesalazine—CHUK—DAP12 interactions—IL6—psoriasis	2.13e-05	0.00021	CbGpPWpGaD
Mesalazine—Feeling abnormal—Prednisone—psoriasis	2.12e-05	0.000133	CcSEcCtD
Mesalazine—Asthenia—Dexamethasone—psoriasis	2.12e-05	0.000133	CcSEcCtD
Mesalazine—Asthenia—Betamethasone—psoriasis	2.12e-05	0.000133	CcSEcCtD
Mesalazine—CHUK—Cytokine Signaling in Immune system—STAT3—psoriasis	2.11e-05	0.000208	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR—IL6—psoriasis	2.11e-05	0.000208	CbGpPWpGaD
Mesalazine—Nervous system disorder—Methotrexate—psoriasis	2.1e-05	0.000133	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—psoriasis	2.1e-05	0.000132	CcSEcCtD
Mesalazine—Gastrointestinal pain—Prednisone—psoriasis	2.1e-05	0.000132	CcSEcCtD
Mesalazine—Nausea—Prednisolone—psoriasis	2.1e-05	0.000132	CcSEcCtD
Mesalazine—IKBKB—Signaling by NGF—NFKB1—psoriasis	2.1e-05	0.000206	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-E—psoriasis	2.1e-05	0.000206	CbGpPWpGaD
Mesalazine—CHUK—Signaling by EGFR in Cancer—IL6—psoriasis	2.09e-05	0.000206	CbGpPWpGaD
Mesalazine—Pruritus—Dexamethasone—psoriasis	2.09e-05	0.000131	CcSEcCtD
Mesalazine—Pruritus—Betamethasone—psoriasis	2.09e-05	0.000131	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—HLA-DRB1—psoriasis	2.08e-05	0.000205	CbGpPWpGaD
Mesalazine—CHUK—Signaling by PDGF—IL6—psoriasis	2.08e-05	0.000205	CbGpPWpGaD
Mesalazine—Skin disorder—Methotrexate—psoriasis	2.08e-05	0.000131	CcSEcCtD
Mesalazine—CHUK—Signaling by NGF—STAT3—psoriasis	2.08e-05	0.000205	CbGpPWpGaD
Mesalazine—Hyperhidrosis—Methotrexate—psoriasis	2.07e-05	0.000131	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—HLA-A—psoriasis	2.07e-05	0.000204	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—NFKBIA—psoriasis	2.07e-05	0.000203	CbGpPWpGaD
Mesalazine—Vomiting—Triamcinolone—psoriasis	2.07e-05	0.00013	CcSEcCtD
Mesalazine—CHUK—Signaling Pathways—CCL20—psoriasis	2.06e-05	0.000202	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CRP—psoriasis	2.06e-05	0.000202	CbGpPWpGaD
Mesalazine—PPARG—Circadian rythm related genes—IL6—psoriasis	2.05e-05	0.000202	CbGpPWpGaD
Mesalazine—Nausea—Hydrocortisone—psoriasis	2.05e-05	0.000129	CcSEcCtD
Mesalazine—Rash—Triamcinolone—psoriasis	2.05e-05	0.000129	CcSEcCtD
Mesalazine—Dermatitis—Triamcinolone—psoriasis	2.05e-05	0.000129	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—psoriasis	2.05e-05	0.000129	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—TYK2—psoriasis	2.04e-05	0.000201	CbGpPWpGaD
Mesalazine—Urticaria—Prednisone—psoriasis	2.04e-05	0.000129	CcSEcCtD
Mesalazine—Headache—Triamcinolone—psoriasis	2.04e-05	0.000128	CcSEcCtD
Mesalazine—Body temperature increased—Prednisone—psoriasis	2.03e-05	0.000128	CcSEcCtD
Mesalazine—Abdominal pain—Prednisone—psoriasis	2.03e-05	0.000128	CcSEcCtD
Mesalazine—Diarrhoea—Dexamethasone—psoriasis	2.02e-05	0.000127	CcSEcCtD
Mesalazine—Diarrhoea—Betamethasone—psoriasis	2.02e-05	0.000127	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—psoriasis	2e-05	0.000126	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—ICAM1—psoriasis	2e-05	0.000197	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—NFKBIA—psoriasis	1.98e-05	0.000195	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.97e-05	0.000193	CbGpPWpGaD
Mesalazine—Musculoskeletal discomfort—Methotrexate—psoriasis	1.95e-05	0.000123	CcSEcCtD
Mesalazine—Dizziness—Dexamethasone—psoriasis	1.95e-05	0.000123	CcSEcCtD
Mesalazine—Dizziness—Betamethasone—psoriasis	1.95e-05	0.000123	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—psoriasis	1.94e-05	0.000122	CcSEcCtD
Mesalazine—IKBKB—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	1.93e-05	0.00019	CbGpPWpGaD
Mesalazine—Nausea—Triamcinolone—psoriasis	1.93e-05	0.000122	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—psoriasis	1.93e-05	0.000121	CcSEcCtD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—STAT3—psoriasis	1.92e-05	0.000189	CbGpPWpGaD
Mesalazine—Dyspnoea—Methotrexate—psoriasis	1.91e-05	0.000121	CcSEcCtD
Mesalazine—PTGS2—Spinal Cord Injury—TP53—psoriasis	1.91e-05	0.000188	CbGpPWpGaD
Mesalazine—Somnolence—Methotrexate—psoriasis	1.91e-05	0.00012	CcSEcCtD
Mesalazine—IKBKB—Immune System—HLA-E—psoriasis	1.9e-05	0.000187	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.89e-05	0.000186	CbGpPWpGaD
Mesalazine—Hypersensitivity—Prednisone—psoriasis	1.89e-05	0.000119	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—HLA-DRB1—psoriasis	1.89e-05	0.000186	CbGpPWpGaD
Mesalazine—Dyspepsia—Methotrexate—psoriasis	1.89e-05	0.000119	CcSEcCtD
Mesalazine—CHUK—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	1.89e-05	0.000186	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—STAT3—psoriasis	1.88e-05	0.000185	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—NFKBIA—psoriasis	1.87e-05	0.000184	CbGpPWpGaD
Mesalazine—Vomiting—Dexamethasone—psoriasis	1.87e-05	0.000118	CcSEcCtD
Mesalazine—Vomiting—Betamethasone—psoriasis	1.87e-05	0.000118	CcSEcCtD
Mesalazine—Decreased appetite—Methotrexate—psoriasis	1.87e-05	0.000118	CcSEcCtD
Mesalazine—IKBKB—Signaling Pathways—CCL20—psoriasis	1.86e-05	0.000183	CbGpPWpGaD
Mesalazine—Rash—Betamethasone—psoriasis	1.86e-05	0.000117	CcSEcCtD
Mesalazine—Rash—Dexamethasone—psoriasis	1.86e-05	0.000117	CcSEcCtD
Mesalazine—Dermatitis—Dexamethasone—psoriasis	1.86e-05	0.000117	CcSEcCtD
Mesalazine—Dermatitis—Betamethasone—psoriasis	1.86e-05	0.000117	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—psoriasis	1.85e-05	0.000117	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—psoriasis	1.85e-05	0.000117	CcSEcCtD
Mesalazine—Headache—Betamethasone—psoriasis	1.85e-05	0.000116	CcSEcCtD
Mesalazine—Headache—Dexamethasone—psoriasis	1.85e-05	0.000116	CcSEcCtD
Mesalazine—Asthenia—Prednisone—psoriasis	1.84e-05	0.000116	CcSEcCtD
Mesalazine—Pain—Methotrexate—psoriasis	1.83e-05	0.000116	CcSEcCtD
Mesalazine—Pruritus—Prednisone—psoriasis	1.82e-05	0.000115	CcSEcCtD
Mesalazine—IKBKB—Adaptive Immune System—ICAM1—psoriasis	1.81e-05	0.000179	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—NFKBIA—psoriasis	1.8e-05	0.000177	CbGpPWpGaD
Mesalazine—Feeling abnormal—Methotrexate—psoriasis	1.77e-05	0.000111	CcSEcCtD
Mesalazine—Diarrhoea—Prednisone—psoriasis	1.76e-05	0.000111	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—psoriasis	1.75e-05	0.000111	CcSEcCtD
Mesalazine—Nausea—Betamethasone—psoriasis	1.75e-05	0.00011	CcSEcCtD
Mesalazine—Nausea—Dexamethasone—psoriasis	1.75e-05	0.00011	CcSEcCtD
Mesalazine—CHUK—Immune System—SOCS1—psoriasis	1.75e-05	0.000172	CbGpPWpGaD
Mesalazine—PTGS2—Spinal Cord Injury—IL6—psoriasis	1.75e-05	0.000172	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—APOE—psoriasis	1.72e-05	0.000169	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.72e-05	0.000169	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—VDR—psoriasis	1.71e-05	0.000168	CbGpPWpGaD
Mesalazine—Urticaria—Methotrexate—psoriasis	1.7e-05	0.000107	CcSEcCtD
Mesalazine—Dizziness—Prednisone—psoriasis	1.7e-05	0.000107	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—psoriasis	1.7e-05	0.000107	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—psoriasis	1.7e-05	0.000107	CcSEcCtD
Mesalazine—CHUK—Innate Immune System—TYK2—psoriasis	1.69e-05	0.000167	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.67e-05	0.000165	CbGpPWpGaD
Mesalazine—Vomiting—Prednisone—psoriasis	1.63e-05	0.000103	CcSEcCtD
Mesalazine—Rash—Prednisone—psoriasis	1.62e-05	0.000102	CcSEcCtD
Mesalazine—Dermatitis—Prednisone—psoriasis	1.62e-05	0.000102	CcSEcCtD
Mesalazine—Headache—Prednisone—psoriasis	1.61e-05	0.000101	CcSEcCtD
Mesalazine—PPARG—Developmental Biology—NFKB1—psoriasis	1.59e-05	0.000157	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—SOCS1—psoriasis	1.59e-05	0.000156	CbGpPWpGaD
Mesalazine—Hypersensitivity—Methotrexate—psoriasis	1.58e-05	9.97e-05	CcSEcCtD
Mesalazine—PTGS1—Metabolism—CARM1—psoriasis	1.56e-05	0.000153	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD8A—psoriasis	1.55e-05	0.000153	CbGpPWpGaD
Mesalazine—Asthenia—Methotrexate—psoriasis	1.54e-05	9.71e-05	CcSEcCtD
Mesalazine—IKBKB—Innate Immune System—TYK2—psoriasis	1.54e-05	0.000151	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—CD4—psoriasis	1.53e-05	0.000151	CbGpPWpGaD
Mesalazine—Nausea—Prednisone—psoriasis	1.52e-05	9.61e-05	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—psoriasis	1.52e-05	9.57e-05	CcSEcCtD
Mesalazine—ALOX5—Metabolism—PPARG—psoriasis	1.5e-05	0.000147	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-B—psoriasis	1.49e-05	0.000147	CbGpPWpGaD
Mesalazine—CHUK—Cytokine Signaling in Immune system—IL6—psoriasis	1.48e-05	0.000145	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.47e-05	0.000145	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—CD4—psoriasis	1.47e-05	0.000145	CbGpPWpGaD
Mesalazine—Diarrhoea—Methotrexate—psoriasis	1.47e-05	9.26e-05	CcSEcCtD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.46e-05	0.000143	CbGpPWpGaD
Mesalazine—CHUK—Signaling by NGF—IL6—psoriasis	1.45e-05	0.000143	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—VEGFA—psoriasis	1.44e-05	0.000142	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—STAT3—psoriasis	1.43e-05	0.000141	CbGpPWpGaD
Mesalazine—Dizziness—Methotrexate—psoriasis	1.42e-05	8.95e-05	CcSEcCtD
Mesalazine—IKBKB—Immune System—CD8A—psoriasis	1.41e-05	0.000139	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—CD4—psoriasis	1.39e-05	0.000137	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-A—psoriasis	1.38e-05	0.000136	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—JUN—psoriasis	1.37e-05	0.000135	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CAT—psoriasis	1.37e-05	0.000135	CbGpPWpGaD
Mesalazine—Vomiting—Methotrexate—psoriasis	1.36e-05	8.6e-05	CcSEcCtD
Mesalazine—IKBKB—Immune System—HLA-B—psoriasis	1.35e-05	0.000133	CbGpPWpGaD
Mesalazine—Rash—Methotrexate—psoriasis	1.35e-05	8.53e-05	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—psoriasis	1.35e-05	8.52e-05	CcSEcCtD
Mesalazine—Headache—Methotrexate—psoriasis	1.34e-05	8.47e-05	CcSEcCtD
Mesalazine—IKBKB—Cytokine Signaling in Immune system—IL6—psoriasis	1.34e-05	0.000132	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—CD4—psoriasis	1.33e-05	0.000131	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.33e-05	0.000131	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CRP—psoriasis	1.32e-05	0.00013	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—NFKB1—psoriasis	1.32e-05	0.00013	CbGpPWpGaD
Mesalazine—IKBKB—Signaling by NGF—IL6—psoriasis	1.32e-05	0.00013	CbGpPWpGaD
Mesalazine—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.3e-05	0.000128	CbGpPWpGaD
Mesalazine—CHUK—Disease—HLA-A—psoriasis	1.28e-05	0.000126	CbGpPWpGaD
Mesalazine—Nausea—Methotrexate—psoriasis	1.27e-05	8.03e-05	CcSEcCtD
Mesalazine—CHUK—Adaptive Immune System—NFKB1—psoriasis	1.27e-05	0.000125	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HLA-DRB1—psoriasis	1.26e-05	0.000124	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-A—psoriasis	1.25e-05	0.000123	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—JUN—psoriasis	1.24e-05	0.000122	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CARM1—psoriasis	1.24e-05	0.000122	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—TNF—psoriasis	1.24e-05	0.000122	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ICAM1—psoriasis	1.21e-05	0.000119	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NFKBIA—psoriasis	1.2e-05	0.000118	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CRP—psoriasis	1.2e-05	0.000118	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—NFKB1—psoriasis	1.2e-05	0.000118	CbGpPWpGaD
Mesalazine—CHUK—Disease—APOE—psoriasis	1.19e-05	0.000117	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.16e-05	0.000114	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—NFKB1—psoriasis	1.15e-05	0.000113	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HLA-DRB1—psoriasis	1.15e-05	0.000113	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SOCS1—psoriasis	1.13e-05	0.000111	CbGpPWpGaD
Mesalazine—CHUK—Disease—NOS2—psoriasis	1.11e-05	0.000109	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ICAM1—psoriasis	1.1e-05	0.000108	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NFKBIA—psoriasis	1.09e-05	0.000107	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—APOE—psoriasis	1.06e-05	0.000105	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SOCS1—psoriasis	1.03e-05	0.000101	CbGpPWpGaD
Mesalazine—PPARG—Developmental Biology—IL6—psoriasis	9.99e-06	9.83e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—TYK2—psoriasis	9.86e-06	9.7e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CAT—psoriasis	9.59e-06	9.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IFNG—psoriasis	9.23e-06	9.09e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—TYK2—psoriasis	9.1e-06	8.96e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—TYK2—psoriasis	8.94e-06	8.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD4—psoriasis	8.92e-06	8.78e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IFNG—psoriasis	8.37e-06	8.24e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—LEP—psoriasis	8.35e-06	8.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOE—psoriasis	8.35e-06	8.22e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—psoriasis	8.28e-06	8.15e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CD4—psoriasis	8.23e-06	8.1e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD4—psoriasis	8.09e-06	7.96e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—JUN—psoriasis	7.98e-06	7.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NFKBIA—psoriasis	7.78e-06	7.66e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NFKB1—psoriasis	7.68e-06	7.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CAT—psoriasis	7.62e-06	7.49e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—LEP—psoriasis	7.57e-06	7.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOE—psoriasis	7.57e-06	7.45e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HLA-A—psoriasis	7.57e-06	7.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—psoriasis	7.51e-06	7.39e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOE—psoriasis	7.45e-06	7.34e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—JUN—psoriasis	7.24e-06	7.12e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOE—psoriasis	7.07e-06	6.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NFKBIA—psoriasis	7.06e-06	6.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NFKB1—psoriasis	6.97e-06	6.86e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—psoriasis	6.9e-06	6.79e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NOS2—psoriasis	6.58e-06	6.48e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PPARG—psoriasis	6.49e-06	6.39e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TYK2—psoriasis	6.38e-06	6.27e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—psoriasis	6.37e-06	6.27e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—psoriasis	6.26e-06	6.16e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOE—psoriasis	5.92e-06	5.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TYK2—psoriasis	5.78e-06	5.69e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL8—psoriasis	5.55e-06	5.46e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TYK2—psoriasis	5.39e-06	5.31e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—JUN—psoriasis	5.16e-06	5.08e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PPARG—psoriasis	5.15e-06	5.07e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL8—psoriasis	5.03e-06	4.95e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NFKB1—psoriasis	4.97e-06	4.89e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD4—psoriasis	4.88e-06	4.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—psoriasis	4.82e-06	4.75e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—JUN—psoriasis	4.68e-06	4.6e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—psoriasis	4.51e-06	4.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NFKB1—psoriasis	4.5e-06	4.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—psoriasis	4.46e-06	4.39e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—psoriasis	4.45e-06	4.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—psoriasis	4.37e-06	4.3e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—psoriasis	4.09e-06	4.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—psoriasis	4.05e-06	3.98e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—psoriasis	3.78e-06	3.72e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—psoriasis	3.41e-06	3.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—psoriasis	3.12e-06	3.07e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—psoriasis	3.09e-06	3.04e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—psoriasis	2.83e-06	2.78e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—psoriasis	2.64e-06	2.6e-05	CbGpPWpGaD
